C. Sessa

1.5k total citations · 1 hit paper
18 papers, 1.2k citations indexed

About

C. Sessa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, C. Sessa has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 7 papers in Reproductive Medicine. Recurrent topics in C. Sessa's work include Ovarian cancer diagnosis and treatment (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Endometrial and Cervical Cancer Treatments (3 papers). C. Sessa is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Endometrial and Cervical Cancer Treatments (3 papers). C. Sessa collaborates with scholars based in Switzerland, Italy and France. C. Sessa's co-authors include Nicoletta Colombo, Silvestro Carinelli, Carolina Marini, Alessandro Colombo, Fabio Landoni, Eleonora Petra Preti, Annalisa Garbi, Michele Peiretti, D. Rollo and Enrico Sartori and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

C. Sessa

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2011 481 citations Nicoletta Colombo, Eleonora Petra Preti et al. Annals of Oncology profile →

Peers

C. Sessa

ONCOL

SURGE

Karin Shih United States

Masamichi Hiura Japan

Taymaa May Canada

Marjan Rouzbahman Canada

Emanuela Veras United States

Jacob Korach Israel

Dongyan Cao China

Janusz Emerich Poland

W. Schröder Germany

Janusz Marcickiewicz Sweden

Karin Shih United States

C. Sessa

546 ×0.9

561 ×1.0

204 ×0.7

ONCOL

195 ×0.8

307 ×1.3

SURGE

Citations per year, relative to C. Sessa C. Sessa (= 1×) peers Karin Shih

Countries citing papers authored by C. Sessa

Since Specialization

Citations

This map shows the geographic impact of C. Sessa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Sessa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Sessa more than expected).

Fields of papers citing papers by C. Sessa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Sessa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Sessa. The network helps show where C. Sessa may publish in the future.

Co-authorship network of co-authors of C. Sessa

This figure shows the co-authorship network connecting the top 25 collaborators of C. Sessa. A scholar is included among the top collaborators of C. Sessa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Sessa. C. Sessa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Froesch, Patrizia, Michael Mark, Sacha I. Rothschild, et al.. (2020). 557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial. Annals of Oncology. 31. S481–S481. 1 indexed citations

Stathis, Anastasios, Dagmar Hess, Roger von Moos, et al.. (2017). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Investigational New Drugs. 35(6). 766–772. 29 indexed citations

Mateo, Joaquı́n, Michael Friedländer, C. Sessa, et al.. (2013). Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation. 49. 17 indexed citations

Fasolo, Angelica, C. Sessa, Luca Gianni, & Massimo Broggini. (2012). Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Annals of Oncology. 24(1). 14–20. 26 indexed citations

Colombo, Nicoletta, Michele Peiretti, Annalisa Garbi, et al.. (2012). Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii20–vii26. 227 indexed citations

Colombo, Nicoletta, Michele Peiretti, Annalisa Garbi, et al.. (2012). Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment. 1 indexed citations

Colombo, Nicoletta, Silvestro Carinelli, Alessandro Colombo, et al.. (2012). Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii27–vii32. 212 indexed citations

Colombo, Nicoletta, Eleonora Petra Preti, Fabio Landoni, et al.. (2011). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 22. vi35–vi39. 481 indexed citations breakdown →

Colombo, Nicoletta, José María Del Campo, Jalid Sehouli, et al.. (2011). 8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials. European Journal of Cancer. 47. S528–S529. 2 indexed citations

10.

Harb, Wael A., C. Sessa, Hal W. Hirte, et al.. (2011). A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3099–3099. 5 indexed citations

11.

Fasolo, Angelica, C. Sessa, Luca Viganò, et al.. (2010). Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3047–3047. 1 indexed citations

12.

Dosso, Sara De, C. Sessa, & Piercarlo Saletti. (2008). Adjuvant therapy for colon cancer: Present and perspectives. Cancer Treatment Reviews. 35(2). 160–166. 38 indexed citations

13.

Soria, Jean‐Charles, C. Sessa, Antonella Perotti, et al.. (2008). Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. Cancer Research. 68(9_Supplement). LB–302. 8 indexed citations

14.

McMeekin, Scott, Josep M. del Campo, Nicoletta Colombo, et al.. (2007). Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies. Journal of Clinical Oncology. 25(18_suppl). 5579–5579. 14 indexed citations

15.

Curigliano, Giuseppe, Carlo M. Cipolla, C. Sessa, et al.. (2006). What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?. Journal of Clinical Oncology. 24(18_suppl). 2006–2006. 5 indexed citations

16.

Wanders, J., W.W. ten Bokkel Huinink, Nikolaos Pavlidis, et al.. (1997). Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non small cell lung cancer (N). European Journal of Cancer. 33. S158–S158. 3 indexed citations

17.

Smyth, J F, A. Bowman, I E Smith, C. Sessa, & Stuart Kaye. (1993). Taxotere is active in small cell lung cancer (SCLC) a phase II trial of the eortc early clinical trials group (ECTG). European Journal of Cancer. 29. S154–S154. 4 indexed citations

18.

Colombo, N., C. Sessa, Fabio Landoni, et al.. (1986). Cisplatin, Vinblastine, and Bleomycin Combination Chemotherapy in Metastatic Granulosa Cell Tumor of the Ovary. Obstetrics and Gynecology. 67(2). 265–268. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact